266 related articles for article (PubMed ID: 6374011)
1. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages.
Vassalli JD; Dayer JM; Wohlwend A; Belin D
J Exp Med; 1984 Jun; 159(6):1653-68. PubMed ID: 6374011
[TBL] [Abstract][Full Text] [Related]
2. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte cultures.
Yamada H; Stephens RW; Nakagawa T; McNicol D
J Biochem; 1988 Dec; 104(6):960-7. PubMed ID: 3149640
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type and tissue-type plasminogen activators have different distributions in cultured bovine capillary endothelial cells.
Moscatelli D
J Cell Biochem; 1986; 30(1):19-29. PubMed ID: 3082899
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
[TBL] [Abstract][Full Text] [Related]
5. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin.
Eaton DL; Scott RW; Baker JB
J Biol Chem; 1984 May; 259(10):6241-7. PubMed ID: 6373753
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of urokinase and thrombin in cultured neural cells.
Wagner SL; Lau AL; Nguyen A; Mimuro J; Loskutoff DJ; Isackson PJ; Cunningham DD
J Neurochem; 1991 Jan; 56(1):234-42. PubMed ID: 1987320
[TBL] [Abstract][Full Text] [Related]
7. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
[TBL] [Abstract][Full Text] [Related]
8. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
9. A fibroblast-derived urokinase-inhibitor differing from protease nexin.
Masuzawa M; Hamazaki H; Nishioka K; Nishiyama S; Ryan TJ
Biochem Biophys Res Commun; 1987 Dec; 149(3):866-73. PubMed ID: 3426613
[TBL] [Abstract][Full Text] [Related]
10. Isolation and interrelationships of the multiple molecular tissue-type and urokinase-type plasminogen activator forms produced by cultured human umbilical vein endothelial cells.
Booyse FM; Scheinbuks J; Lin PH; Traylor M; Bruce R
J Biol Chem; 1988 Oct; 263(29):15129-38. PubMed ID: 3139666
[TBL] [Abstract][Full Text] [Related]
11. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.
Chapman HA; Stone OL; Vavrin Z
J Clin Invest; 1984 Mar; 73(3):806-15. PubMed ID: 6368589
[TBL] [Abstract][Full Text] [Related]
12. Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Rao JS; Baker JB; Morantz RA; Kimler B; Evans R; Festoff BW
Cancer Res; 1990 Aug; 50(16):5039-44. PubMed ID: 2116223
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.
Wohlwend A; Belin D; Vassalli JD
J Exp Med; 1987 Feb; 165(2):320-39. PubMed ID: 2434595
[TBL] [Abstract][Full Text] [Related]
14. A fibrinolytic inhibitor of human alveolar macrophages. Induction with endotoxin.
Chapman HA; Stone OL
Am Rev Respir Dis; 1985 Sep; 132(3):569-75. PubMed ID: 3898943
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54,000) from cultured human endothelial cells indistinguishable from urinary urokinase.
Booyse FM; Osikowicz G; Feder S; Scheinbuks J
J Biol Chem; 1984 Jun; 259(11):7198-205. PubMed ID: 6539333
[TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma.
Stump DC; Thienpont M; Collen D
J Biol Chem; 1986 Sep; 261(27):12759-66. PubMed ID: 3091604
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
Wun TC; Reich E
J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
[TBL] [Abstract][Full Text] [Related]
18. Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity.
Benjamin LA; McGarry RC; Hart DA
Cancer Chemother Pharmacol; 1989; 25(1):25-31. PubMed ID: 2590998
[TBL] [Abstract][Full Text] [Related]
19. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes.
Manchanda N; Schwartz BS
J Biol Chem; 1991 Aug; 266(22):14580-4. PubMed ID: 1907280
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages.
Saksela O; Hovi T; Vaheri A
J Cell Physiol; 1985 Jan; 122(1):125-32. PubMed ID: 2578131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
